The short version of heptapeptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-12. Anything still debated is marked as such rather than presented as settled.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
=== Associated conditions === Joint hypermobility may be associated with other conditions. These include ADHD, autism, dyspraxia, fibromyalgia, hereditary connective tissue disorders, mitral valve prolapse, and anxiety disorders such as panic disorder. Joint hypermobility does not cause these other conditions. Most people with joint hypermobility do not have them. In people who do, the underlying cause can be a general syndrome that affects the whole body and brain (such as Autism or Fetal Alcohol Spectrum Disorders), or a genetic condition or disease that affects certain tissues (such as Ehlers-Danlos syndrome or lupus). Hypermobility may be a risk factor for temporomandibular joint dysfunction.
Hodgkin and Huxley approached the problem by developing a set of differential equations for the parameters that govern the ion channel states, known as the Hodgkin-Huxley equations. These equations have been extensively modified by later research, but form the starting point for most theoretical studies of action potential biophysics.
During his leadership, Xi has supported and pursued a greater political and economic integration of Hong Kong to mainland China, including through projects such as the Hong Kong–Zhuhai–Macau Bridge. He has pushed for the Greater Bay Area project, which aims to integrate Hong Kong, Macau, and nine other cities in Guangdong. Xi's integration efforts have led to deeper economic links between mainland China and Hong Kong, as well as decreased freedoms and the weakening of Hong Kong's distinct identity from mainland China. Many of the views held by the central government and eventually implemented in Hong Kong were outlined in a white paper published by the State Council Information Office in 2014 named The Practice of the 'One Country, Two Systems' Policy in the Hong Kong Special Administrative Region, which outlined that the scope of Hong Kong's autonomy is not inherent, but solely determined by the Central Authorities' delegation of power. Under Xi, the Chinese government also declared the Sino-British Joint Declaration to be legally void. In August 2014, the Standing Committee of the National People's Congress (NPCSC) made a decision allowing universal suffrage for the 2017 election of the chief executive of Hong Kong, also requiring the candidates to "love the country, and love Hong Kong," as well as other measures that ensured the Chinese leadership would be the ultimate decision-maker on the selection, leading to protests, and the eventual rejection of the reform bill in the Legislative Council due to a walk-out by the pro-Beijing camp to delay to vote.
Sources: en.wikipedia.org
Cyclone Tam causes significant power outages in Northland and leads to the cancellation of flights and ferry services in Auckland. 17 April – Cyclone Tam causes over 6,000 properties in Northland, the Coromandel Peninsula, Bay of Plenty and Gisborne to lose power overnight. 18 April – Cyclone Tam causes flooding to roads and highways in the Coromandel Peninsula. Flooding and strong-winds are also reported in the Far North District, leading to road closures and flight disruptions. 19 April – Cyclone Tam causes flooding, thunderstorms and travel disruptions in Auckland. Local authorities issue an emergency alert. 20 April: Auckland authorities issue a second emergency alert in response to flooding and thunderstorms caused by Cyclone Tam. 70 protesters affiliated with the Happy Valley Coalition occupy a fast-tracked coal mine on the Denniston Plateau near Westport. 21 April – Cyclone Tam begins easing, despite heavy rain and thunderstorms across New Zealand. Power companies work on restoring power to Northland homes. The Auckland Council inspects 16 flood-damaged properties. 22 April – Power companies restore power to most houses in Northland, with 25 Far North homes remaining disconnected. 23 April – Police remove the last remaining protesters from a coal mine in the Denniston Plateau. Seven people were charged with trespassing while three were arrested. 24 April – A fire breaks out at a recycling plant in the Wairau Valley in Auckland's North Shore, causing significant damage including a chemical spill contaminating several beaches in the North Shore.
Apoptosis A form of programmed cell death involved in development and disease. In the nervous system, apoptosis shapes neural circuits and removes damaged neurons. Arachnoid mater The middle of the three layers of the meninges that surround the brain and spinal cord, located between the dura mater and the pia mater. Arousal A physiological and psychological state of alertness and readiness, regulated by the reticular activating system and neurotransmitters such as norepinephrine and dopamine. Astrocyte A star-shaped glial cell in the central nervous system involved in maintaining the blood–brain barrier, regulating neurotransmitter levels, and supporting neuronal function. Ataxia A neurological symptom characterized by a lack of coordination and balance, typically caused by damage to the cerebellum or its connections. Auditory cortex A part of the temporal lobe responsible for processing auditory information, including pitch, volume, and sound localization. Autonomic nervous system A division of the peripheral nervous system that controls involuntary physiological processes, including heart rate, digestion, and respiration. It is divided into the sympathetic and parasympathetic systems. Axon A long, slender projection of a neuron that conducts action potentials away from the cell body to synaptic terminals, where neurotransmitters are released. Axon hillock The cone-shaped region of a neuron’s soma where the axon originates and action potentials are typically initiated.
The transition from wakefulness to sleep (REM sleep or NREM sleep) is associated with a reduction in upper-airway muscle tone. During REM sleep, the muscle tone of the throat and neck, as well as that of the vast majority of skeletal muscles, is almost completely relaxed. This allows the tongue and soft palate/oropharynx to relax, reducing airway patency and potentially impeding or completely obstructing air flow into the lungs during inspiration, resulting in reduced respiratory ventilation. If reductions in ventilation are associated with sufficiently low blood-oxygen levels or with sufficiently high breathing efforts against an obstructed airway, neurological mechanisms may trigger a sudden interruption of sleep, called a neurological arousal. This arousal can cause an individual to gasp for air and awaken. These arousals rarely result in complete awakening but can have a significant negative effect on the restorative quality of sleep. In significant cases of OSA, one consequence is sleep deprivation resulting from the repetitive disruption and recovery of sleep activity. This sleep interruption in Stage 3 NREM sleep (also called slow-wave sleep) and in REM sleep can interfere with normal growth patterns, healing, and immune response, especially in children and young adults. The fundamental cause of OSA is a blocked upper airway, usually behind the tongue and epiglottis, whereby the otherwise patent airway, in an erect, awake patient, collapses when the patient lies on his or her back and loses muscle tone upon entering deep sleep.
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.